Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-996

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Carmot Australia First Pty Ltd · Phase 1 · Completed · Enrollment 94

NCT05814107

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1: CT-996 SAD Cohort 1n/rn/rn/rn/r
Part 1: CT-996 SAD Cohort 2n/rn/rn/rn/r
Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5n/rn/rn/rn/r
Part 1: CT-996 SAD Cohort 4n/rn/rn/rn/r
Part 1: CT-996 SAD Cohort 6n/rn/rn/rn/r
Part 1: Placebo SAD Cohortn/rn/rn/rn/r
Part 2: CT-996 MAD Cohort 1n/rn/rn/rn/r
Part 2: CT-996 MAD Cohort 2n/rn/rn/rn/r
Part 2: CT-996 MAD Cohort 3n/rn/rn/rn/r
Part 2: Placebo MAD Cohortn/rn/rn/rn/r
Part 3: CT-996 MD T2DM Cohort 1n/rn/rn/rn/r
Part 3: CT-996 MD T2DM Cohort 2n/rn/rn/rn/r
Part 3: Placebo MD T2DM Cohortn/rn/rn/rn/r

Not shown

  • Part 1: CT-996 SAD Cohort 1: endpoint not reported
  • Part 1: CT-996 SAD Cohort 2: endpoint not reported
  • Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5: endpoint not reported
  • Part 1: CT-996 SAD Cohort 4: endpoint not reported
  • Part 1: CT-996 SAD Cohort 6: endpoint not reported
  • Part 1: Placebo SAD Cohort: endpoint not reported
  • Part 2: CT-996 MAD Cohort 1: endpoint not reported
  • Part 2: CT-996 MAD Cohort 2: endpoint not reported
  • Part 2: CT-996 MAD Cohort 3: endpoint not reported
  • Part 2: Placebo MAD Cohort: endpoint not reported
  • Part 3: CT-996 MD T2DM Cohort 1: endpoint not reported
  • Part 3: CT-996 MD T2DM Cohort 2: endpoint not reported
  • Part 3: Placebo MD T2DM Cohort: endpoint not reported